The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pleural thickening - Fibrothorax
Publications
Pleuropulmonary Toxicity of Another Anti-Parkinson's Drug: Cabergoline.
The open respiratory medicine journal. 2009;3:90-3
Pleural effusion and thickening due to cabergoline use in a patient with Parkinson's disease.
European journal of internal medicine. 2005;16(2):129-131
Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
Heart (British Cardiac Society). 2004;90(8):e47
Fibrosis associated with dopamine agonist therapy in Parkinson's disease.
Clinical neuropharmacology. 2003;26(3):109-11
Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
Mayo Clinic proceedings. 1999;74(4):371-5
Pleuropulmonary changes induced by ergoline drugs.
The European respiratory journal. 1996;9(5):1013-9
Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.
Archives of internal medicine. 1988;148(10):2231-6